 |
|
|
| |
Perceptions of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) From
Patients in the CAB + RPV Implementation Study in European Locations (CARISEL)
|
| |
| |
HIV Drug Therapy Glasgow; October 23-26, 2022; Virtual and Glasgow, Scotlan
Thomas Lutz1, Eliette Jeanmaire2, Joaquin Portilla3, Jenny Scherzer4, Rekha Trehan5, Miguel Pascaul-Bernáldez6, Rebecca DeMoor7, Mounir Ait-Khaled5, Monica Hadi8, Savita Bakhshi Anand8, Emma L. Low8, Maggie Czarnogorski9, Cassidy A. Gutner9
1Infektio Research, Frankfurt, Germany; 2Service de Maladies Infectieuses et Tropicales, Hôpital Brabois, CHRU de Nancy, Vandoeuvre-les-Nancy, France; 3Hospital General Universitario de Alicante, Alicante, Spain; 4ViiV Healthcare GmbH, Munich, Germany; 5ViiV Healthcare, Brentford, United Kingdom; 6ViiV Healthcare, Madrid, Spain; 7GlaxoSmithKline, Collegeville, PA, United States; 8Evidera, London, United Kingdom;
9ViiV Healthcare, Research Triangle Park, NC, United States
|
| |
|
|
|
|
|
